Table 3.
May 2010–August 2015: mean changes in self-efficacy, mental well-being, function and worst and average pain and pain interference from baseline (pre-PMP) to consecutive follow-ups.
| N | Pre-PMP Mean (SD) |
Post-PMP Mean (SD) |
p-value | |
|---|---|---|---|---|
| PSEQ (0–60) | ||||
| Post | 143 | 20.6 (10.7) | 29.8 (11.6)*** | <.001** |
| 10 weeks | 96 | 20.6 (10.3) | 28.6 (11.7) | <.001** |
| 6 months | 71 | 22.6 (10.8) | 25.8 (12.9) | .010* |
| 12 months | 49 | 22.2 (10.0) | 27.7 (13.7) | .002* |
| WEMWBS (14–70) | ||||
| Post | 121 | 35.2 (9.7) | 44.0 (10.1)*** | <.001** |
| 10 weeks | 78 | 35.5 (10.4) | 43.5 (10.5)*** | <.001** |
| 6 months | 62 | 36.8 (9.9) | 40.7 (11.4)*** | .001** |
| 12 months | 39 | 36.9 (11.7) | 41.8 (12.5)*** | <.001** |
| BPI worst pain (0–10) | ||||
| Post | 90 | 7.6 (1.8) | 7.6 (1.6) | .735 |
| 10 weeks | 59 | 7.5 (1.8) | 7.3 (1.7) | .469 |
| 6 months | 43 | 7.4 (2.0) | 7.6 (1.6) | .643 |
| 12 months | 21 | 6.6 (2.3) | 7.8 (1.2) | .055 |
| BPI average pain (0–10) | ||||
| Post | 90 | 6.6 (1.5) | 6.5 (1.5) | .342 |
| 10 weeks | 59 | 6.5 (1.6) | 6.5 (1.6) | .826 |
| 6 months | 43 | 6.3 (1.7) | 6.3 (1.4) | .832 |
| 12 months | 21 | 5.9 (2.1) | 6.3 (1.2) | .242 |
| BPI interference (0–10) | ||||
| Post | 89 | 7.2 (1.9) | 6.7 (1.9) | .027* |
| 10 weeks | 57 | 7.3 (1.8) | 6.6 (2.0) | .004* |
| 6 months | 40 | 6.7 (2.1) | 7.1 (1.9) | .380 |
| 12 months | 19 | 7.0 (1.9) | 7.5 (1.6) | .389 |
| STST | ||||
| Post | 98 | 9.2 (6.6) | 12.5 (5.6) | <.001** |
PMP: pain management programme; PSEQ: Pain Self-Efficacy Questionnaire; WEMWBS: Warwick–Edinburgh Mental Well-being Scale; BPI: Brief Pain Inventory; STST: sit-to-stand test; MCID: minimal important clinical difference.
*
Significant at .05; **significant at .001; ***MCID met.